

## JC10 Rec'd PCT/PTO 2

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Sanders et al.

Application No.: 10/537,280

Filed: 5/27/2005

Title: Binding Partners for the Thyrotropin

Receptor and Uses Thereof

Attorney Docket No.: URQU.P-016

Group Art Unit:

Examiner:

Assistant Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313

## INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants request that the references listed on form PTO 1449, which is attached, be made of record in the US Patent and Trademark Office in the file relating to the above-captioned application. Copies of the listed non-US and non-patent references are enclosed.

This paper is submitted within three months of the filing date. Accordingly, no fee should be due. The Commissioner is authorized to charge any fees due in connection with this paper or credit any overpayment to Deposit Account No. 15-0610.

This paper and the attachments named herein are being deposited with the United States Postal Service ith sufficient postage as first class mail and addressed to

with sufficient postage as first class mail and addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on

JUL 1 8 2005

Name Sandra J. Lahmann

Signature Dougla (Vachma

Respectfully submitted,

Marina T. Larson, Ph.D

Attorney/Agent for Applicant(s)

Reg. No. 32038

(970) 468 6600

PTO/SB/08a (08-03) Approved use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. stitute for form 49A/PTO Complete if Known Application Number 10/537,280 INFORMATION DISCLOSURE Filing Date First Named Inventor STATEMENT BY APPLICANT Sanders et al. Art Unit (Use as many sheets as necessary) Examiner Name Sheet 1 of 2 Attorney Docket Number URQU.P-016

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
				Applicant of Cited Document			
				Segre et al.			
	<u>:</u>	US- ·	·		,		
		US-		·			
		US-		·			
		US-					
		US-					
		US-			,		
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		us-					
		US-					
		US-					

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	· T <sup>6</sup>		
/CMW/		WO 03/018632	03-06-2003	Smith et al.				
		WO 91/09137	06-27-1991	Rapoport				
		WO 99/64865	12-16-1999	Sanders et al.		:		
W		EP 1 078 986	02-28-2001	Hattori et al.				
/CMW/		EP 0 719 858	07-03-1996	Matsuba et al.	-			
					•			
	<u> </u>							
						<u> </u>		

Examiner Signature /Cherie M. Woodward/ Date Considered 03/31/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of US PTO Patent Documents at <a href="www.upsto.gov">www.upsto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond

Substitute for form 1449B/PTO  INFORMATION DISCLOSURE  STATEMENT BY APPLICANT  (Use as many sheets as necessary)  Sheet  2  Of  Application Number  10/537,280  Filing Date  First Named Inventor  Art Unit  Examiner Name  Attorney Docket Number  UPOUR 016	Criati ale i api	or more reconstruction	rese, ne person	o are require	od to respond to a collection of in	termation drifess it displays a valid OMB control number		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use as many sheets as necessary)  Filing Date  Filing Date  First Named Inventor  Art Unit  Examiner Name	Substitute for form 1449B/PTO				Complete if Known			
STATEMENT BY APPLICANT  (Use as many sheets as necessary)  First Named Inventor Sanders et al.  Art Unit Examiner Name	11.505	SMATION DI	201 001	55	Application Number	10/537,280		
Art Unit (Use as many sheets as necessary)  Examiner Name	INFORMATION DISCLOSURE				Filing Date			
. (Use as many sheets as necessary) Examiner Name	STATEMENT BY APPLICANT			NT.	First Named Inventor	Sanders et al.		
					Art Unit			
Sheet 2 of 2 Attorney Docket Number LIPOLE 016	(Use as many sheets as necessary)				Examiner Name			
2 7 LEGING BOOKE WAINDER ORGO.F-010	Sheet	2	of	2 ·	Attorney Docket Number	URQU.P-016		

		NON PATENT LITERATURE DOCUMENTS					
Examiner Initials* Cit		The german journes, contain, containing, cro. /, date, page(5), volunte-1550c number(5), page(5), page(5), volunte-1550c number(5), page(5), page(5), volunte-1550c number(5), page(5), pa					
		CHAZENBALK ET AL., Thyroid-stimulating autoantibodies in Graves disease preferentially recognize the free A subunit, Journal of Clinical Investigation, 07/2002, Page(s) 209-217, Volume 110, Number 2					
200000000000000000000000000000000000000		CUNDIFF ET AL., Studies using recombinant fragments of human TSH receptor reveal apparent diversity in the binding specificities, Journal of Clinical Endocrinology and Metabolism, 09/2001, Page(s) 4254-4260, Volume 86, Number 9					
	,	VAN DER HEIJDEN ET AL., Limitations of the semisynthetic library approach for obtaining human monoclonal autoantibodies to the thyrotropin receptor of Graves' disease, Clinical and Experimental Immunology, 1999, Page(s) 205-212, Volume 118					
		AKAMIZU ET AL., Characterization of Recombinant Monoclonal Antithyrotropin Receptor Antibodies (TSHRAbs) Derived from Lymphocytes of Patients with Graves' Disease, Endocrinology, 1999, Page(s) 1594-1601, Volume 140, Number 4					
000000000000000000000000000000000000000		SHEPHERD ET AL., Identification of an important thyrotrophin binding site on the human thyrotrophin receptor using monoclonal antibodies, Molecular and Cellular Endocrinology, 1999, Page(s) 197-206, Volume 149					
	,	SANDERS ET AL., The Interaction of TSH Receptor Autoantibodies with I-Labelled TSH Receptor, The Journal of Clinical Endocrinology & Metabolism, 1999, Page(s) 3797-3802, Volume 84, Number 10					
		VALENTE ET AL., Monoclonal antibodies to the thyrotropin receptor: Stimulating and blocking antibodies derived from the lymphocytes of patients with Graves disease, Proc. Natl. Acad. Sci., 11/1982, Page(s) 6680-6684, Volume 79					
/CMW/		MISRAHI ET AL., Human thyroid stimulatory hormone receptor (TSHR) mRNA, complete cds, NCBI Accession No: M32215, 1995					
			••				

Examiner	/Cherie M. Woodward/	Date -	03/31/2008
Signature	<u>.</u> <u></u>	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.